» Articles » PMID: 28448435

A Resident's Perspective of Ovarian Cancer

Overview
Specialty Radiology
Date 2017 Apr 28
PMID 28448435
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Identifying, understanding, and curing disease is a lifelong endeavor for any medical practitioner. Equally as important is to be cognizant of the impact a disease has on the individual suffering from it, as well as on their family. Ovarian cancer is the leading cause of death from gynecologic malignancies. Symptoms are vague, and the disease is generally at an advanced stage at diagnosis. Efforts have been made to develop methods to identify ovarian cancer at earlier stages, thus improving overall mortality. Transvaginal ultrasound (TVUS), with and without laboratory tests, can be used to screen for ovarian cancer. For over thirty years, the University of Kentucky Markey Cancer Center Ovarian Cancer Screening Program has been studying the efficacy of TVUS for detecting early stage ovarian cancer. After 285,000+ TVUS examinations provided to over 45,000 women, the program has demonstrated that regular TVUS examinations can detect ovarian cancer at early stages, and that survival is increased in those women whose ovarian cancer was detected with screening and who undergo standard treatment. These results demonstrate the utility of TVUS as an efficacious method of ovarian cancer screening.

Citing Articles

The role of RNA methyltransferase METTL3 in gynecologic cancers: Results and mechanisms.

Zhang Y, Zhang N Front Pharmacol. 2023; 14:1156629.

PMID: 37007040 PMC: 10060645. DOI: 10.3389/fphar.2023.1156629.


Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer.

Zamwar U, Anjankar A Cureus. 2022; 14(10):e30561.

PMID: 36415372 PMC: 9676071. DOI: 10.7759/cureus.30561.


Dysregulation of lncRNA-miRNA-mRNA Interactome as a Marker of Metastatic Process in Ovarian Cancer.

Pronina I, Uroshlev L, Moskovtsev A, Zaichenko D, Filippova E, Fridman M Biomedicines. 2022; 10(4).

PMID: 35453574 PMC: 9031843. DOI: 10.3390/biomedicines10040824.


Identification of the Mutational Landscape of Gynecological Malignancies.

Chava S, Gupta R J Cancer. 2020; 11(16):4870-4883.

PMID: 32626534 PMC: 7330690. DOI: 10.7150/jca.46174.


Ovarian Cancer Screening: Lessons about Effectiveness.

Pavlik E Diagnostics (Basel). 2017; 8(1).

PMID: 29286290 PMC: 5871984. DOI: 10.3390/diagnostics8010001.


References
1.
Jayson G, Kohn E, Kitchener H, Ledermann J . Ovarian cancer. Lancet. 2014; 384(9951):1376-88. DOI: 10.1016/S0140-6736(13)62146-7. View

2.
Maxim L, Niebo R, Utell M . Screening tests: a review with examples. Inhal Toxicol. 2014; 26(13):811-28. PMC: 4389712. DOI: 10.3109/08958378.2014.955932. View

3.
Gupta D, Lis C . Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. J Ovarian Res. 2009; 2:13. PMC: 2764643. DOI: 10.1186/1757-2215-2-13. View

4.
Alvarado-Cabrero I, Navani S, Young R, Scully R . Tumors of the fimbriated end of the fallopian tube: a clinicopathologic analysis of 20 cases, including nine carcinomas. Int J Gynecol Pathol. 1997; 16(3):189-96. DOI: 10.1097/00004347-199707000-00001. View

5.
Goff B, Mandel L, Drescher C, Urban N, Gough S, Schurman K . Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2006; 109(2):221-7. DOI: 10.1002/cncr.22371. View